Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radio-protective effect of sodium meclofenamate. A prospective clinical trial

Journal Article · · Journal of Medicine (Westbury, New York); (USA)
OSTI ID:5024909
Twentyfour patients treated with irradiation to either their pelvis or their chest for neoplastic disease were included in a randomized study of radioprotection with sodium meclofenamate (Meclomen) (SM). Seventeen patients received SM 100 mg, p.os, t.i.d., and seven received placebo. The long-range radiation related chronic gastrointestinal and urinary tract toxicity was diminished by SM. At 12 months post irradiation, SM treated patients experienced less gastrointestinal and urinary symptoms, as well as less measured bladder contraction, than the controls. Acute gastrointestinal signs of radiotoxicity, however, seemed to have been enhanced by SM. The treated patients suffered from nausea, vomiting, and diarrhea. These acute toxic effects were temporary and reversible.
OSTI ID:
5024909
Journal Information:
Journal of Medicine (Westbury, New York); (USA), Journal Name: Journal of Medicine (Westbury, New York); (USA) Vol. 20:3-4; ISSN JNMDB; ISSN 0025-7850
Country of Publication:
United States
Language:
English